BioHarvest Sciences (BHST) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
7 May, 2026Mission and vision
Focused on addressing unmet health and wellness needs with patentable plant compounds produced sustainably and economically.
Aims to discover, develop, manufacture, and democratize life-changing plant-based compounds for global health and wellness while preserving the planet.
Technology and platform
Invented botanical synthesis, isolating and maximizing phytonutrients by growing only plant cells, not whole plants.
Over $100M invested in a patented platform with 14 granted patents and multiple pending.
Facilities optimized for industrial production, requiring low CapEx and offering high ROI; $5M investment can yield $60M in annual revenue.
Process enables consistent, clean, non-GMO, and highly potent compounds with significant environmental and economic advantages.
Product portfolio and growth engines
Two main growth engines: direct-to-consumer (D2C) packaged products and CDMO services for plant-based compounds.
Flagship product VINIA® has achieved over $84M in sales since 2021, with 85,000+ active customers and strong clinical validation.
Expanding product lines include hydration powders, chews, coffee, tea, and future launches based on olive and pomegranate cell powders.
CDMO division has signed four deals across cosmetics, pharma, nutraceuticals, and sweeteners, with a robust pipeline and multi-billion-dollar market opportunities.
Latest events from BioHarvest Sciences
- Proprietary plant cell culture drives revenue growth and expansion, with $37–$40M projected this year.BHST
H.C. Wainwright 28th Annual Global Investment Conference - Patented plant cell culture platform drives scalable growth and strong revenue outlook.BHST
Q3 Investor Summit Group Virtual Conference 2026 - Patented cell culture platform secures $20–30M fragrance deal, targets $40M revenue and profitability.BHST
Canaccord Genuity's 46th Annual Growth Conference - Proprietary plant cell platform and D2C/CDMO engines drive projected $37–40M 2026 revenue.BHST
Corporate presentation - Secured first CDMO fragrance contract, driving revenue growth and revised guidance for 2026.BHST
Q2 2026 - Q1 revenue up 8% to $8.5M, CDMO revenue up 135%, net loss $2.6M, gross margin 59%.BHST
Q1 2026 - Plant-based exosome breakthrough enables new high-margin markets and a novel skincare launch.BHST
Status Update - Q1 revenue up 47% to $7.9M, gross margin 58.5%, and major CDMO contract advanced.BHST
Q1 2025 - Q4 revenue up 62%, gross margin at 57%, and major CDMO deal drive strong 2025 outlook.BHST
Q4 2024